MHRA: Releases Field Safety Notices 31 August 4 September 2026 for UK Devices

• The MHRA released several Field Safety Notices (FSNs) between 31 August and 4 September 2026, covering various medical devices and in-vitro diagnostics.
• Recipients of FSNs from manufacturers are legally required to act on them, while the MHRA publishes them for information only.
• Affected products include the Acu-Loc 2 VDR Plt Std L, a general-purpose multi-parameter bedside monitor, patient health record information systems, and an Aripiprazole therapeutic drug monitoring IVD reagent.
• Other devices under alert are orthopaedic prostheses cements, external imaging lesion localization markers, an orthopaedic cement preparation/delivery kit, and a peripheral artery endovascular stent-graft.
• Compliance officers and legal counsel must review these notices to ensure immediate action and mitigate legal and regulatory risks.

Compliance officers and legal counsel for medical device manufacturers, distributors, or healthcare providers must review these latest MHRA Field Safety Notices 31 August 4 September 2026 to identify if their products or operations are impacted and ensure immediate compliance with any required actions, including product recalls or safety modifications, to mitigate legal and regulatory risks.

The Medicines and Healthcare products Regulatory Agency (MHRA) has recently published a series of Field Safety Notices (FSNs) covering the period from 31 August to 4 September 2026. These alerts pertain to a range of medical devices and in-vitro diagnostics (IVDs) that require attention from manufacturers, distributors, and healthcare providers within the UK. The notices serve as critical updates regarding potential safety issues or required corrective actions for specific products.

Among the devices highlighted in these MHRA medical device alerts UK are orthopaedic components, patient monitoring systems, and diagnostic reagents. The publication of these FSNs underscores the ongoing commitment to post-market surveillance and patient safety in the United Kingdom. Stakeholders are advised to review these updates promptly to ascertain any direct impact on their operations or product portfolios.

While the MHRA disseminates these FSNs for informational purposes, the responsibility for action lies squarely with the recipients. Any entity that receives a Field Safety Notice directly from a manufacturer is legally obligated to act upon it without delay. This imperative ensures that necessary safety measures, such as product recalls, modifications, or enhanced user guidance, are implemented swiftly to protect public health.

Compliance officers and legal counsel for medical device manufacturers, distributors, or healthcare providers must review these latest MHRA Field Safety Notices 31 August 4 September 2026 to identify if their products or operations are impacted. Ensuring immediate compliance with any required actions, including product recalls or safety modifications, is crucial to mitigate legal and regulatory risks. For specific inquiries regarding a particular FSN, the MHRA advises contacting the respective manufacturer directly, as they are best positioned to provide detailed guidance and support.

The recent tranche of Medicines and Healthcare products Regulatory Agency FSNs includes several distinct product categories. For instance, the Acu-Loc 2 VDR Plt Std L FSN is associated with MHRA references 40679952, 2026/008/028/601/038, 40687391, and 2026/008/013/601/181. A general-purpose multi-parameter bedside monitor is also subject to an alert, identified by MHRA references 40686601 and 2026/008/005/601/078. Patient health record information systems are flagged with MHRA references 40681769, 2026/008/028/601/128, 40693494, 2026/008/013/601/145, and the specific reference FSN-HME-2026-02-EN.

Further alerts concern orthopaedic prostheses cements, linked to MHRA references 40679488, 2026/008/013/601/021, 40697690, and 2026/006/025/601/076. Imaging lesion localization markers, external, specifically models 8801071, 8801074, and 8801075, are noted with MHRA references 40709365, 2026/008/028/601/055, 40725654, and 2026/008/026/601/039. An Aripiprazole therapeutic drug monitoring IVD recall is also part of this series, with the reagent identified by MHRA references 40710070 and 2026/008/024/601/101. Additionally, an orthopaedic cement preparation/delivery kit (MHRA ref: 40719475, 2026/009/002/601/137) and a peripheral artery endovascular stent-graft (MHRA ref: 40709534, 2026/008/028/601/167) complete the list of specific UK medical device compliance updates.

The regular issuance of Field Safety Notices by the MHRA is a cornerstone of UK medical device compliance updates, providing essential transparency and guidance for the healthcare sector. For organizations operating within this regulated environment, understanding and responding to these notices is not merely a best practice but a fundamental regulatory requirement. Failure to address identified safety concerns can lead to significant legal repercussions, reputational damage, and, most importantly, compromised patient safety.

Access to historical FSNs is also maintained, with records available for notices published since January 2020 and November 2014 directly from the MHRA. Older FSNs, predating November 2014, can be found on the National Archives website. This comprehensive record-keeping ensures that all relevant parties can trace the history of device safety alerts, aiding in thorough due diligence and ongoing risk management strategies.

Compliance officers and legal counsel for medical device manufacturers, distributors, or healthcare providers must review these latest MHRA Field Safety Notices to identify if their products or operations are impacted and ensure immediate compliance with any required actions, including product recalls or safety modifications, to mitigate legal and regulatory risks.

Source: Original reporting via GOV.UK